The antibiotic pipeline is nearly empty — and the economics are the reason, not the science
A few quietly significant data points from the last few years: Achaogen, Melinta, and Tetraphase all received FDA approval for novel antibiotics and then went bankrupt. Approval is supposed to be the finish line. For antibiotics, it turned out to be the moment you discover the business doesn't work.
The core problem: antibiotics are taken for 7-14 days. Statins and antihypertensives are taken for decades. New antibiotics also get stewarded — "keep it in reserve for resistant cases" — meaning even successful drugs generate low volume by design. And the moment patents expire, generics compete away the premium. There's no long-tail revenue.
Most pipeline candidates are derivatives of existing classes. Bacteria already have evolutionary playbooks against those. Novel-mechanism antibiotics (the ones that would actually solve AMR long-term) take 15+ years and most fail late.
The most interesting structural response so far: the UK's NHS now pays a flat annual subscription fee for access to two novel antibiotics, regardless of volume used. You pay for the option to deploy, not per-course. A few other countries are running variants. The US passed PASTEUR Act language pointing in this direction but hasn't funded it.
AMR kills roughly 1.2 million people per year directly. Some projections have it overtaking cancer deaths by 2050.
Is the subscription/pull model the real fix, or does this one eventually need nationalized R&D — the way basic vaccine infrastructure did?
0 replies